COMP <GO>
CTMX vs UNH // PIOTROSKI F-SCORE QUALITY
CytomX Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: CTMX 0
— UNH 10
▲ PIOTROSKI F-SCORE QUALITY LEADER: UNH
LAST: $2.29 (-2.97%) • MKT CAP: $499.0M
piotroski-score
1/9
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTMX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTMX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.50% | 11.47% | -31.97 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.19% | 6.48% | -21.67 | UNH | /fcf-yield <GO> |
| Operating Margin | -29.30% | 4.82% | -34.12 | UNH | /operating-margins <GO> |
| Net Profit Margin | -22.80% | 3.14% | -25.94 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -44.80% | 6.46% | -51.26 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 3.12 | -2.92 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 1/9 | 7/9 | -6.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.7 | 59.2 | -16.50 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $499.0M | $368.83B | -$368.33B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTMX REV | UNH REV | CTMX GROSS % | UNH GROSS % | CTMX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $76.2M | $447.57B | — | 88.7% | -$75.8M | $16.07B |
| FY 2024 | $138.1M | $400.28B | — | 88.3% | -$86.5M | $20.70B |
| FY 2023 | $101.2M | $371.62B | — | 89.6% | -$56.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTMX // BETA —
UNH // BETA 0.33